Use of Hmgb1 inhibitor glycyrrhizin significantly reduced the tumor size (Figure 4(c)) and the production of IL-23 and IL-17, and recombined mouse IL-23 administration abrogated the reduced IL-17 expression and decreased tumor size induced by Hmgb1 inhibitor (Figures 4(e)-4(f)). Here, IL23A is linked to neoplasm.